# NovoCure Ltd > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/NovoCure Ltd). ## Overview NovoCure Ltd develops and commercializes Tumor Treating Fields (TTFields) therapy, a non-invasive cancer treatment delivered through portable medical devices and arrays worn by patients. The company is headquartered in the United States and serves oncology markets across the U.S., Europe, Japan, and other international markets through direct and partner-based distribution. ## Products & services • Optune Gio for glioblastoma (GBM) • Optune Lua for NSCLC and mesothelioma • Optune Pax for pancreatic cancer • TTFields therapy systems and patient support services • Physician training and certification programs - **TTFields oncology devices** (85%) — Portable tumor-treating field systems used to deliver therapy for approved cancer indications. - **Consumable arrays and accessories** (10%) — Replacement arrays and related consumables used with the therapy devices. - **Patient support and service programs** (5%) — Training, onboarding, and support services that help patients use the therapy at home. - Optune Gio for glioblastoma (GBM) - Optune Lua for NSCLC and mesothelioma - Optune Pax for pancreatic cancer - TTFields therapy systems and patient support services - Physician training and certification programs ## Customers NovoCure sells primarily to oncology patients through healthcare providers, with therapy adoption driven by physicians who prescribe and certify for use of the system. Its end users include patients with brain, thoracic, and abdominal cancers, while hospitals and distributors are important channels in certain markets such as Japan and Greater China. Reimbursement and physician training are central to customer adoption because the therapy is device-based, home-used, and indication-specific. - **Glioblastoma patients** (primary) — Patients with GBM treated with Optune Gio, typically through neuro-oncology and oncology centers. - **NSCLC patients** (primary) — Patients with non-small cell lung cancer treated with Optune Lua in approved markets. - **Pancreatic cancer patients** (primary) — Patients with pancreatic cancer treated with Optune Pax in the U.S. and other approved markets. - **Hospitals and channel partners** (secondary) — Hospitals and local partners that distribute the product and support patient onboarding in some countries. - Patients with GBM, NSCLC, mesothelioma, and pancreatic cancer - Medical oncologists who prescribe therapy and manage treatment plans - Specialty oncologists treating brain, thorax, or abdomen cancers - Hospitals and distributors in markets using non-direct channels - Payers and reimbursement systems that influence access and uptake ## Geography NovoCure is a U.S.-based company with revenue generated across the United States and a broad international footprint, including France, Germany, Japan, Greater China, and other markets. The company’s disclosures show meaningful revenue contribution from Europe and other international markets, while Greater China is served through a licensing and collaboration structure with Zai. Geography matters because reimbursement, regulatory approvals, and channel design differ by market and directly affect adoption. - **United States** (40%) — Estimated from MD&A references to U.S. revenue and offsetting claims-related items. - **Europe** (45%) — Estimated from disclosures highlighting France, Germany, and remaining international markets. - **Greater China** (5%) — Commercialized through Zai under a strategic collaboration. - **Japan** (5%) — Served through hospital-based distribution arrangements. - **Rest of world** (5%) — Other international markets not separately disclosed. - United States is a core market for approved indications and reimbursement - France and Germany are important European revenue contributors - Other international markets contribute through active patient growth - Greater China is commercialized through a Zai collaboration - Japan uses hospital-based distribution rather than direct-to-patient ## Strategy NovoCure’s strategy centers on expanding adoption of TTFields in approved indications while pursuing additional regulatory approvals and geographic expansion. The company also relies on physician training, patient support, and collaboration partners to scale commercialization in complex oncology markets. Its longer-term direction is to broaden the addressable cancer set beyond CNS and lung while maintaining access through reimbursement and channel partnerships. - **Increase adoption in approved indications** (short-term) — Revenue depends on patient starts and continued use of TTFields therapy. - **Broaden regulatory approvals and market access** (medium-term) — New indications and reimbursement pathways expand the addressable market. - **Scale global commercialization through partners and training** (medium-term) — The therapy requires physician certification and local market execution. - Grow penetration in active markets for approved indications - Expand into additional geographic markets where approvals allow - Pursue new oncology indications beyond CNS and lung - Invest in physician education and certification - Use collaborations to commercialize in Greater China and other markets ## Risks NovoCure is exposed to regulatory, reimbursement, and commercialization risk because its products require approval, physician training, and payer access in each market. The business also depends on a small number of core products, single-source suppliers for some components, and third-party collaborators in certain geographies, which increases execution and supply-chain sensitivity. - **Concentration in a small number of products** [high] — Business prospects depend heavily on a few approved TTFields indications. - **Regulatory and reimbursement delays** [high] — Adoption depends on approvals and payer coverage in each market. - **Single-source supply dependence** [high] — Loss of a supplier could delay shipments or clinical studies. - **Cybersecurity and patient data exposure** [medium] — The company handles sensitive patient treatment and health information. - **Partner execution risk** [medium] — Some markets rely on collaborators that control commercialization efforts. - Dependence on Optune Gio, Optune Lua, and Optune Pax - Regulatory approval and reimbursement timing can delay market expansion - Single-source suppliers could disrupt product shipments - Cybersecurity or patient-data breaches could harm trust and operations - Partner execution risk in Greater China and other collaborative markets ## Accounting Revenue recognition is central because NovoCure recognizes product and collaboration revenue across multiple markets and arrangements, including the Zai agreement. Inventory, service pool equipment, and rental/operating lease treatment can materially affect cost of revenues and asset balances because the therapy uses reusable field equipment and replacement arrays. Estimates around inventory obsolescence, equipment loss or damage, uncertain tax positions, and impairment reviews also matter because the business relies on specialized devices and long-lived assets. - **Revenue recognition** — Can affect timing and comparability of reported revenue - **Inventory obsolescence** — Affects cost of revenues and gross margin - **Service pool equipment and operating leases** — Affects balance sheet assets and operating expenses - **Impairment of long-lived assets** — May create non-cash charges - **Uncertain tax positions** — Can change tax expense and liabilities - Revenue recognition for product sales and Zai collaboration revenue - Inventory valuation and obsolescence for arrays and device components - Service pool equipment and rental/operating lease accounting - Provisions for lost or damaged equipment - Impairment and useful-life estimates for long-lived assets - Uncertain tax positions across multiple jurisdictions --- *Last updated: 2026-04-29T04:42:05.623527+00:00*